Trial
NCT02793219
Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
The University of Texas Health Science Center, Houston
Collaborators
—
Condition
Prostate Cancer
Intervention
Sipuleucel-T
Why stopped
Dendreon was sold and new company decided not to fund study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-10-30